Here are the 10-K annual reports from Avita Medical, Inc. (RCEL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCEL filings page.
AVITA Medical, Inc. reports in its annual filing that it remains a high-growth, loss-making acute wound care company built around its RECELL autologous cell harvesting platform and new products Cohealyx and PermeaDerm.
The company posted a net loss of $48.6 million in 2025 and has an accumulated deficit of $408.4 million, while targeting long-term profitability through broader use of RECELL in burns, traumatic and surgical wounds and international expansion. AVITA added a new senior secured credit facility of up to $60 million, drawing $50 million and using part of the proceeds to refinance prior debt. It emphasizes extensive FDA approvals, growing clinical and health-economic evidence, and a sizable patent and trademark portfolio as competitive strengths, but warns that execution, reimbursement, regulatory, manufacturing, cybersecurity, and high leverage risks could materially affect results.